New Current

See all
Featured Perspectives
July 18, 2024

Renalys Pharma announces first patient dosed in registrational Phase III clinical trial of sparsentan for IgA nephropathy in Japan

Read More

Catalyzing Transpacific Partnership

The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an “on-the-ground”, local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors.

Meet the Team
Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.”
Nobuo Hanai, PhD
Our Charter
Learn more